EGFR and non-small cell lung carcinoma: Results of sensitivity analyses indicated that the possible independent relationship between concomitant use of AS and poor survival of NSCLC patients taking TKIs was not primarily driven by either of the included studies and remained significant in patients with EGFR mutations.